Improvement in Function after Lasmiditan Treatment: Post Hoc Analysis of Data from Phase 3 Studies

ConclusionAll doses of lasmiditan resulted in an improvement in migraine-related functional disability that persisted to 48 h. In SAMURAI + SPARTAN, a significant difference from placebo was observed as early as 1 h post dose.Trial registration at clinicaltrials.govSAMURAI (NCT02439320), SPARTAN (NCT02605174), and GLADIATOR (NCT02565186).

http://link.springer.com/10.1007/s40120-020-00185-5

Source: Neurology and Therapy - May 22, 2020 Category: Neurology Source Type: research